Compare HY & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HY | OCGN |
|---|---|---|
| Founded | 1991 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 555.3M | 474.8M |
| IPO Year | 2012 | 2014 |
| Metric | HY | OCGN |
|---|---|---|
| Price | $29.41 | $0.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $50.00 | $12.17 |
| AVG Volume (30 Days) | 111.1K | ★ 6.8M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,769,300,000.00 | N/A |
| Revenue This Year | N/A | $12.33 |
| Revenue Next Year | $7.84 | $10.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.41 | $0.69 |
| 52 Week High | $41.30 | $2.73 |
| Indicator | HY | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.16 | 33.51 |
| Support Level | $28.99 | N/A |
| Resistance Level | $33.55 | $1.12 |
| Average True Range (ATR) | 1.14 | 0.06 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 46.51 | 16.35 |
Hyster Yale Inc designs, engineers, manufactures, sells, and services a comprehensive line of lift trucks, attachments, aftermarket parts, and technology solutions marketed globally under the Hyster and Yale brand names. The company has four segments, which include three in the lift truck business as discussed below, as well as Bolzoni S.p.A. (Bolzoni). The majority of its revenue is generated from Lift Trucks. Geographically, it operates in America, EMEA, and JAPIC regions, of which maximum revenue is generated from its business in America, which includes lift truck operations in the U.S., Canada, Mexico, Brazil, and Latin America.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").